Literature DB >> 23007157

IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation.

Rhine R Shen1, Alicia Y Zhou, Eejung Kim, Elgene Lim, Hasem Habelhah, William C Hahn.   

Abstract

NF-κB transcription factors are central regulators of inflammation and when dysregulated contribute to malignant transformation. IκB kinase ε (IKKε; IKKi, encoded by IKBKE) is a breast oncogene that is amplified in 30% of breast cancers and drives transformation in an NF-κB-dependent manner. Here we demonstrate that IKKε interacts with and phosphorylates tumor necrosis factor receptor-associated factor 2 (TRAF2) at Ser11 in vitro and in vivo. This activity promotes Lys63-linked TRAF2 ubiquitination and NF-κB activation and is essential for IKKε transformation. Breast cancer cells that depend on IKKε expression for survival are also dependent on TRAF2. This work defines TRAF2 phosphorylation to be one key effector of IKKε-induced mammary epithelial cell transformation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007157      PMCID: PMC3497603          DOI: 10.1128/MCB.00468-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

1.  Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB.

Authors:  Hasem Habelhah; Shoichi Takahashi; Ssang-Goo Cho; Takayuki Kadoya; Toshiki Watanabe; Ze'ev Ronai
Journal:  EMBO J       Date:  2004-01-08       Impact factor: 11.598

2.  The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO.

Authors:  Derek W Abbott; Andrew Wilkins; John M Asara; Lewis C Cantley
Journal:  Curr Biol       Date:  2004-12-29       Impact factor: 10.834

3.  A rapid method for determining protein kinase phosphorylation specificity.

Authors:  Jessica E Hutti; Emily T Jarrell; James D Chang; Derek W Abbott; Peter Storz; Alex Toker; Lewis C Cantley; Benjamin E Turk
Journal:  Nat Methods       Date:  2004-10       Impact factor: 28.547

4.  TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40.

Authors:  M Rothe; V Sarma; V M Dixit; D V Goeddel
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

Review 5.  A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways.

Authors:  Daniel Krappmann; Claus Scheidereit
Journal:  EMBO Rep       Date:  2005-04       Impact factor: 8.807

6.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer.

Authors:  Eli Pikarsky; Rinnat M Porat; Ilan Stein; Rinat Abramovitch; Sharon Amit; Shafika Kasem; Elena Gutkovich-Pyest; Simcha Urieli-Shoval; Eithan Galun; Yinon Ben-Neriah
Journal:  Nature       Date:  2004-08-25       Impact factor: 49.962

7.  IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.

Authors:  Florian R Greten; Lars Eckmann; Tim F Greten; Jin Mo Park; Zhi-Wei Li; Laurence J Egan; Martin F Kagnoff; Michael Karin
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

8.  The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.

Authors:  Andrew Kovalenko; Christine Chable-Bessia; Giuseppina Cantarella; Alain Israël; David Wallach; Gilles Courtois
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

9.  CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.

Authors:  Eirini Trompouki; Eudoxia Hatzivassiliou; Theodore Tsichritzis; Hannah Farmer; Alan Ashworth; George Mosialos
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

10.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

View more
  34 in total

1.  Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Authors:  Thanh U Barbie; Gabriela Alexe; Amir R Aref; Shunqiang Li; Zehua Zhu; Xiuli Zhang; Yu Imamura; Tran C Thai; Ying Huang; Michaela Bowden; John Herndon; Travis J Cohoon; Timothy Fleming; Pablo Tamayo; Jill P Mesirov; Shuji Ogino; Kwok-Kin Wong; Matthew J Ellis; William C Hahn; David A Barbie; William E Gillanders
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis.

Authors:  Alexey V Sorokin; Binoj C Nair; Yongkun Wei; Kathryn E Aziz; Valentina Evdokimova; Mien-Chie Hung; Junjie Chen
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

3.  The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.

Authors:  Suhu Liu; Anna E Marneth; Gabriela Alexe; Sarah R Walker; Helen I Gandler; Darwin Q Ye; Katherine Labella; Radhika Mathur; Patricia A Toniolo; Michelle Tillgren; Prafulla C Gokhale; David Barbie; Ann Mullally; Kimberly Stegmaier; David A Frank
Journal:  Blood Adv       Date:  2018-12-11

4.  IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.

Authors:  Mihir Rajurkar; Kyvan Dang; Maite G Fernandez-Barrena; Xiangfan Liu; Martin E Fernandez-Zapico; Brian C Lewis; Junhao Mao
Journal:  Cancer Res       Date:  2017-01-09       Impact factor: 12.701

5.  Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

Authors:  Arantza Azpilikueta; Elixabet Bolaños; Valerie Lang; Sara Labiano; Maria A Aznar; Iñaki Etxeberria; Alvaro Teijeira; Maria E Rodriguez-Ruiz; Jose L Perez-Gracia; Maria Jure-Kunkel; Juan M Zapata; Manuel S Rodriguez; Ignacio Melero
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

6.  TRAF2 Ser-11 Phosphorylation Promotes Cytosolic Translocation of the CD40 Complex To Regulate Downstream Signaling Pathways.

Authors:  Lauren M Workman; Laiqun Zhang; Yumei Fan; Weizhou Zhang; Hasem Habelhah
Journal:  Mol Cell Biol       Date:  2020-04-13       Impact factor: 4.272

7.  Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors.

Authors:  Jason Harquail; Nicolas LeBlanc; Carine Landry; Nicolas Crapoulet; Gilles A Robichaud
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-21       Impact factor: 2.673

8.  Structure and ubiquitination-dependent activation of TANK-binding kinase 1.

Authors:  Daqi Tu; Zehua Zhu; Alicia Y Zhou; Cai-hong Yun; Kyung-Eun Lee; Angela V Toms; Yiqun Li; Gavin P Dunn; Edmond Chan; Tran Thai; Shenghong Yang; Scott B Ficarro; Jarrod A Marto; Hyesung Jeon; William C Hahn; David A Barbie; Michael J Eck
Journal:  Cell Rep       Date:  2013-02-28       Impact factor: 9.423

Review 9.  TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification.

Authors:  Lauren M Workman; Hasem Habelhah
Journal:  Cell Signal       Date:  2013-04-21       Impact factor: 4.315

10.  IκB Kinase ε Is an NFATc1 Kinase that Inhibits T Cell Immune Response.

Authors:  Junjie Zhang; Hao Feng; Jun Zhao; Emily R Feldman; Si-Yi Chen; Weiming Yuan; Canhua Huang; Omid Akbari; Scott A Tibbetts; Pinghui Feng
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.